DoW Toxic Exposures Clinical Trial Award

In plain English

Defense Health Agency Contracting Activity - DHACA (Department of Defense) is accepting applications for this grant until Nov 19, 2026 (8 days left).

The agency expects to make 1 award and estimated total program funding is $4,500,000.

Eligibility is listed as unrestricted (open to any type of applicant), subject to any clarification in the listing.

The listing says cost sharing or matching is not required.

Built only from the fields in the Grants.gov listing. Always confirm on the official listing.

• Unrestricted (open to any type of entity above, subject to clarification in the listing)

Excerpt from the official synopsis on Grants.gov (shortened; read the full text on the official listing):

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO) . …

Read the full listing on Grants.gov →